Kyverna Therapeutics (KYTX) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kyverna Therapeutics is the larger company by market cap ($382.2 million vs $364.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | SCTX |
|---|---|---|
| Share price | $6.18 | $19.23 |
| Market cap | $382.19M | $364.06M |
| 1-day change | +0.16% | +9.45% |
| YTD return | -34.36% | — |
| 1-year return | +14.05% | — |
| EPS (TTM) | $-2.93 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.67 | $39.60 |
| 52-week low | $5.96 | $13.50 |
| Distance from 52-week high | -54.79% | -51.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +391.91% | +196.41% |
| Average volume | 898.60K | 357.50K |
| Shares outstanding | 61.84M | 18.93M |
| Employees | 149 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
KYTX vs SCTX FAQ
Which is bigger, Kyverna Therapeutics or Scribe Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $382.19M compared with $364.06M for Scribe Therapeutics (SCTX).
Are Kyverna Therapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.